WO2007003582A3 - Serum-free stable transfection and production of recombinant human proteins in human cell lines - Google Patents

Serum-free stable transfection and production of recombinant human proteins in human cell lines Download PDF

Info

Publication number
WO2007003582A3
WO2007003582A3 PCT/EP2006/063705 EP2006063705W WO2007003582A3 WO 2007003582 A3 WO2007003582 A3 WO 2007003582A3 EP 2006063705 W EP2006063705 W EP 2006063705W WO 2007003582 A3 WO2007003582 A3 WO 2007003582A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
serum
cell lines
stable transfection
human cell
Prior art date
Application number
PCT/EP2006/063705
Other languages
French (fr)
Other versions
WO2007003582A2 (en
Inventor
Carola Schroeder
Cathleen Wegmann
Haiyan Ding
Original Assignee
Octapharma Ag
Carola Schroeder
Cathleen Wegmann
Haiyan Ding
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35427852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007003582(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to DK06777525.4T priority Critical patent/DK1896590T3/en
Priority to CA2611708A priority patent/CA2611708C/en
Priority to AU2006265173A priority patent/AU2006265173B2/en
Priority to BRPI0613721-0A priority patent/BRPI0613721B1/en
Priority to MX2007015370A priority patent/MX2007015370A/en
Priority to ES06777525.4T priority patent/ES2574584T3/en
Priority to JP2008518853A priority patent/JP5925407B2/en
Priority to KR1020077030563A priority patent/KR101320489B1/en
Priority to US11/993,604 priority patent/US8871439B2/en
Application filed by Octapharma Ag, Carola Schroeder, Cathleen Wegmann, Haiyan Ding filed Critical Octapharma Ag
Priority to EP06777525.4A priority patent/EP1896590B1/en
Priority to SI200632064A priority patent/SI1896590T1/en
Publication of WO2007003582A2 publication Critical patent/WO2007003582A2/en
Publication of WO2007003582A3 publication Critical patent/WO2007003582A3/en
Priority to IL187676A priority patent/IL187676A/en
Priority to NO20076087A priority patent/NO343221B1/en
Priority to US14/506,107 priority patent/US9273325B2/en
Priority to US15/011,760 priority patent/US9512457B2/en
Priority to US15/369,068 priority patent/US9796986B2/en
Priority to IL250575A priority patent/IL250575A0/en
Priority to IL266122A priority patent/IL266122A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21001—Chymotrypsin (3.4.21.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/04—Immortalised cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/007—Vectors comprising a special origin of replication system tissue or cell-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/60—Vectors comprising a special origin of replication system from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
PCT/EP2006/063705 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines WO2007003582A2 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
BRPI0613721-0A BRPI0613721B1 (en) 2005-06-30 2006-06-29 Method for preparing an immortalized human cell line and method for recombinant production of a human target protein
SI200632064A SI1896590T1 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines
EP06777525.4A EP1896590B1 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines
MX2007015370A MX2007015370A (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines.
CA2611708A CA2611708C (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines
ES06777525.4T ES2574584T3 (en) 2005-06-30 2006-06-29 Stable serum-free transfection and production of recombinant human proteins in human cell lines
JP2008518853A JP5925407B2 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines
KR1020077030563A KR101320489B1 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines
US11/993,604 US8871439B2 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines
DK06777525.4T DK1896590T3 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines
AU2006265173A AU2006265173B2 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines
IL187676A IL187676A (en) 2005-06-30 2007-11-27 Serum-free stable transfection and production of recombinant human proteins in human cell lines
NO20076087A NO343221B1 (en) 2005-06-30 2007-11-27 Serum-free stable transfection and production of recombinant human proteins in human cell lines
US14/506,107 US9273325B2 (en) 2005-06-30 2014-10-03 Serum-free stable transfection and production of recombinant human proteins in human cell lines
US15/011,760 US9512457B2 (en) 2005-06-30 2016-02-01 Serum-free stable transfection and production of recombinant human proteins in human cell lines
US15/369,068 US9796986B2 (en) 2005-06-30 2016-12-05 Serum-free stable transfection and production of recombinant human proteins in human cell lines
IL250575A IL250575A0 (en) 2005-06-30 2017-02-13 Serum-free stable transfection and production of recombinant human proteins in human cell lines
IL266122A IL266122A (en) 2005-06-30 2019-04-18 Serum-free stable transfection and production of recombinant human proteins in human cell lines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05105965A EP1739179A1 (en) 2005-06-30 2005-06-30 Serum-free stable transfection and production of recombinant human proteins in human cell lines
EP05105965.7 2005-06-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/993,604 A-371-Of-International US8871439B2 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines
US14/506,107 Division US9273325B2 (en) 2005-06-30 2014-10-03 Serum-free stable transfection and production of recombinant human proteins in human cell lines

Publications (2)

Publication Number Publication Date
WO2007003582A2 WO2007003582A2 (en) 2007-01-11
WO2007003582A3 true WO2007003582A3 (en) 2007-05-18

Family

ID=35427852

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/063705 WO2007003582A2 (en) 2005-06-30 2006-06-29 Serum-free stable transfection and production of recombinant human proteins in human cell lines

Country Status (20)

Country Link
US (4) US8871439B2 (en)
EP (2) EP1739179A1 (en)
JP (3) JP5925407B2 (en)
KR (1) KR101320489B1 (en)
CN (2) CN101233238A (en)
AU (1) AU2006265173B2 (en)
BR (1) BRPI0613721B1 (en)
CA (1) CA2611708C (en)
DK (1) DK1896590T3 (en)
ES (1) ES2574584T3 (en)
HU (1) HUE028028T2 (en)
IL (3) IL187676A (en)
MX (1) MX2007015370A (en)
NO (1) NO343221B1 (en)
PL (1) PL1896590T3 (en)
RU (1) RU2453597C2 (en)
SI (1) SI1896590T1 (en)
UA (1) UA99700C2 (en)
WO (1) WO2007003582A2 (en)
ZA (1) ZA200711013B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101190605B1 (en) * 2007-06-15 2012-10-15 재단법인 목암생명공학연구소 Method for manufacturing active recombinant blood coagulation factor ix
ES2391613T3 (en) 2008-06-24 2012-11-28 Octapharma Ag A procedure to purify coagulation factor VIII
JP2012500250A (en) 2008-08-21 2012-01-05 オクタファルマ アクチェン ゲゼルシャフト Recombinantly produced human factor VIII and factor IX
JP5592080B2 (en) * 2009-05-08 2014-09-17 株式会社日立製作所 Cell culture method and cell culture system
CN101906438B (en) * 2009-06-05 2013-04-24 苏州泽璟生物制药有限公司 Method for expressing and producing recombinant human blood coagulation factors VII in animal cells
PL2499165T3 (en) 2009-11-13 2017-04-28 Grifols Therapeutics Inc. Von willebrand factor (vwf)-containing preparations, and methods, kits, and uses related thereto
ES2670827T3 (en) 2010-03-30 2018-06-01 Octapharma Ag Process for purification of granulocyte colony stimulating factor, G-CSF
AU2011234521B2 (en) 2010-03-30 2015-04-23 Octapharma Ag A process for purifying Vitamin K dependent proteins such as coagulation factor IX
DK2947148T3 (en) 2010-04-20 2017-09-18 Octapharma Ag NEW STABILIZER FOR PHARMACEUTICAL PROTEINS
DK3626737T3 (en) 2011-05-13 2024-02-05 Octapharma Ag METHOD FOR INCREASING THE PRODUCTIVITY OF EUKARYOTIC CELLS IN THE PRODUCTION OF RECOMBINANT FVIII
CN102277379B (en) * 2011-08-18 2013-07-24 中国科学院遗传与发育生物学研究所 Expression vector for expressing coagulation factor VIII and application thereof
CN103031277B (en) * 2011-09-29 2015-07-15 重庆大学 Application of mechano-growth factor in preparation of serum-free cultured tolerant type mammal engineering cell
CN103305540B (en) * 2012-03-14 2015-03-25 齐鲁制药有限公司 Plasmid for determination of biological activity and preparation method thereof
CA3051089C (en) 2012-05-02 2022-04-12 Life Technologies Corporation High yield transient expression in mammalian cells using unique pairing of high density growth and transfection medium and expression enhancers
BR112015027373A2 (en) * 2013-05-03 2017-08-29 Fujifilm Diosynth Biotechnologies Uk Ltd EXPRESSION PROCESS
HUE050484T2 (en) * 2013-09-12 2020-12-28 Biomarin Pharm Inc Aav vectors comprising a gene encoding factor viii
WO2015107222A1 (en) 2014-01-20 2015-07-23 Octapharma Ag A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag
WO2016070166A2 (en) * 2014-11-02 2016-05-06 Arcturus Therapeutics, Inc. Messenger una molecules and uses thereof
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
US20210124000A1 (en) 2018-05-04 2021-04-29 Fraunhofer-Gesellschaft zur Foerderung der angewandten Forschung eingetragener Verein Arterial spin labeling with evaluation of inversion state of magnetization
JP7497356B2 (en) * 2018-12-06 2024-06-10 ビーエーエスエフ ソシエタス・ヨーロピア Aqueous suspensions containing zeolite materials and zirconium chelate complexes - Patent Application 20070229933
CN110438066B (en) * 2019-08-19 2021-01-12 杭州百凌生物科技有限公司 Mammalian cell line 293C18P capable of being stably passaged and capable of being cultured in suspension, and preparation method and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1010762A1 (en) * 1998-12-02 2000-06-21 Aventis Behring Gesellschaft mit beschränkter Haftung DNA constructs of blood clotting factors and P-Selectin
WO2001014529A1 (en) * 1999-08-25 2001-03-01 Immunex Corporation Compositions and methods for improved cell culture
WO2002008221A2 (en) * 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
WO2004095027A1 (en) * 2003-04-22 2004-11-04 Baxter International Inc. Diagnostic assay for anti-von willebrand factor cleaving protease (adamts13) antibodies
EP1533380A2 (en) * 1999-04-15 2005-05-25 Crucell Holland B.V. Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577259B2 (en) 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
DK165506C (en) 1984-01-12 1993-04-19 Chiron Corp PROTEIN PREPARATION WITH COAGULATING ACTIVITY AND PROCEDURE FOR PREPARING THEREOF
FI86885C (en) 1984-04-20 1992-10-26 Genentech Inc Method for Preparation of Human Recombinant Factor VIII and Nucleic Acid Sequences and Vectors Used thereto
JPS6171774A (en) 1984-09-14 1986-04-12 Sony Corp Beam current controller of television camera device
EP0218712B1 (en) 1985-04-12 1992-02-26 Genetics Institute, Inc. Novel procoagulant proteins
JPS63500636A (en) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 DNA encoding multipotent granulocyte colony stimulating factor
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0253870B1 (en) 1986-01-03 1993-03-31 Genetics Institute, Inc. Method for producing factor viii:c-type proteins
FI98829C (en) 1986-01-27 1997-08-25 Chiron Corp Process for Preparation of Recombinant Protein Complex with Human Factor VIII: C Activity
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
EP0251843A1 (en) 1986-06-06 1988-01-07 Transgene S.A. Process for the preparation of factor VIII from mammalian cells
DK155388C (en) 1986-07-08 1989-10-23 Palle Pedersen LOCK
ATE63335T1 (en) 1986-07-11 1991-05-15 Miles Inc PRODUCTION OF RECOMBINANT PROTEIN.
NO872932L (en) 1986-07-18 1988-01-19 Gist Brocades Nv PROCEDURE FOR THE MANUFACTURE OF PROTEINS WITH FACTOR VIVILITY BY MICROBIAL HOSTS, EXPRESSING VECTORS, HOSTING CELLS, ANTIBIOTICS.
IL84168A0 (en) 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
FR2619314B1 (en) 1987-08-11 1990-06-15 Transgene Sa FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
JPH084495B2 (en) * 1988-08-19 1996-01-24 帝人株式会社 Method for culturing adherent animal cells
DK0500734T3 (en) 1989-11-17 1998-03-30 Chiron Corp Protein complexes with factor VIII: C activity as well as their production
SE465222C5 (en) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab A recombinant human factor VIII derivative and process for its preparation
DE4204694C3 (en) 1992-02-01 1995-10-12 Octapharma Ag Method for obtaining highly pure, virus-inactivated factor VIII by means of anion exchange chromatography
ES2118386T3 (en) 1993-02-09 1998-09-16 Octapharma Ag PROCEDURE FOR THE INACTIVATION OF VIRUSES THAT ARE NOT PROVIDED WITH LIPID ENVELOPES.
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
DK128093D0 (en) 1993-11-12 1993-11-12 Novo Nordisk As HIS UNKNOWN RELATIONSHIPS
US6136865A (en) 1995-05-20 2000-10-24 Octapharma Ag Method for reduction of the infectiousness of potentially infectious material
AU735763B2 (en) * 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
NZ506944A (en) * 1998-04-17 2003-10-31 Nestle Sa Immortalised keratinocyte cell line derived from normal human skin tissues
US6210924B1 (en) * 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
CA2252972C (en) * 1998-11-26 2012-09-18 National Research Council Of Canada Serum-free production of recombinant proteins and adenoviral vectors
JP2002542813A (en) * 1999-04-29 2002-12-17 レウコテク アクティーゼルスカブ Expression of heparin binding protein in recombinant mammalian cells
CA2404163C (en) 2000-03-22 2009-09-29 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
WO2002099089A1 (en) * 2001-06-04 2002-12-12 Corixa Corporation Compositions and methods for high-level, large-scale production of recombinant proteins
US20040180438A1 (en) * 2002-04-26 2004-09-16 Pachuk Catherine J. Methods and compositions for silencing genes without inducing toxicity
DE50308030D1 (en) 2002-11-29 2007-10-04 Boehringer Ingelheim Pharma NEW NEOMYCIN PHOSPHOTRANSFERASE GENES AND METHOD FOR SELECTION OF HIGHLY PRODUCTIVE RECOMBINANT CELLS
US7217566B2 (en) 2003-03-24 2007-05-15 Invitrogen Corporation Attached cell lines
AU2004259398A1 (en) * 2003-06-27 2005-02-03 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
JP2005073509A (en) * 2003-08-28 2005-03-24 Nihon Pharmaceutical Co Ltd Method for producing human antithrombin
US7727762B2 (en) * 2003-10-03 2010-06-01 Keiichi Fukuda Method of inducing the differentiation of stem cells into myocardial cells
JP4705473B2 (en) * 2003-11-06 2011-06-22 株式会社リプロセル Stem cell cryopreservation method and system
CN1875100A (en) * 2003-11-06 2006-12-06 埃克森希特医疗股份有限公司 BACE455, an alternative splice variant of the human beta-secretase
CN101952856B (en) 2008-02-15 2013-03-27 皇家飞利浦电子股份有限公司 Apparatus for segmenting an object comprising sub-objects

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1010762A1 (en) * 1998-12-02 2000-06-21 Aventis Behring Gesellschaft mit beschränkter Haftung DNA constructs of blood clotting factors and P-Selectin
EP1533380A2 (en) * 1999-04-15 2005-05-25 Crucell Holland B.V. Recombinant protein production in a human cell comprising at least one E1 protein of adenovirus
WO2001014529A1 (en) * 1999-08-25 2001-03-01 Immunex Corporation Compositions and methods for improved cell culture
WO2002008221A2 (en) * 2000-07-20 2002-01-31 Neurogen Corporation Capsaicin receptor ligands
WO2004095027A1 (en) * 2003-04-22 2004-11-04 Baxter International Inc. Diagnostic assay for anti-von willebrand factor cleaving protease (adamts13) antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BERG D T ET AL: "HIGH-LEVEL EXPRESSION OF SECRETED PROTEINS FROM CELLS ADAPTED TO SERUM-FREE SUSPENSION CULTURE", BIOTECHNIQUES, INFORMA LIFE SCIENCES PUBLISHING, WESTBOROUGH, MA, US, vol. 14, no. 6, June 1993 (1993-06-01), pages 972 - 978, XP002059902, ISSN: 0736-6205 *
DUROCHER Y ET AL: "High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 30, no. 2, 15 January 2002 (2002-01-15), pages E9 - 1, XP002261468, ISSN: 0305-1048 *
GOODWIN E C ET AL: "THE 3'-FLANKING SEQUENCE OF THE BOVINE GROWTH HORMONE GENE CONTAINS NOVEL ELEMENTS REQUIRED FOR EFFICIENT AND ACCURATE POLYADENYLATION", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 23, 1992, pages 16330 - 16334, XP002357739, ISSN: 0021-9258 *
ZAWORSKI P ET AL: "SERUM-FREE TRANSFECTION AND SELECTION IN CHINESE HAMSTER OVARY (CHO) CELLS", BIOTECHNIQUES, INFORMA LIFE SCIENCES PUBLISHING, WESTBOROUGH, MA, US, vol. 15, no. 5, 1993, pages 863 - 864,866, XP000891597, ISSN: 0736-6205 *

Also Published As

Publication number Publication date
KR20080028891A (en) 2008-04-02
PL1896590T3 (en) 2016-10-31
JP6754414B2 (en) 2020-09-09
KR101320489B1 (en) 2013-10-30
WO2007003582A2 (en) 2007-01-11
IL266122A (en) 2019-06-30
US9512457B2 (en) 2016-12-06
HUE028028T2 (en) 2016-11-28
IL250575A0 (en) 2017-03-30
AU2006265173B2 (en) 2011-07-28
RU2453597C2 (en) 2012-06-20
BRPI0613721B1 (en) 2022-05-24
DK1896590T3 (en) 2016-06-13
CA2611708A1 (en) 2007-01-11
MX2007015370A (en) 2008-02-11
US20150044720A1 (en) 2015-02-12
IL187676A0 (en) 2008-08-07
US20170152523A1 (en) 2017-06-01
AU2006265173A1 (en) 2007-01-11
ES2574584T3 (en) 2016-06-20
CN101233238A (en) 2008-07-30
US20160177362A1 (en) 2016-06-23
JP2019058173A (en) 2019-04-18
ZA200711013B (en) 2008-10-29
US8871439B2 (en) 2014-10-28
RU2008103319A (en) 2009-08-10
NO343221B1 (en) 2018-12-10
NO20076087L (en) 2008-01-28
BRPI0613721A2 (en) 2011-02-08
EP1896590A2 (en) 2008-03-12
JP2008544750A (en) 2008-12-11
EP1896590B1 (en) 2016-03-23
CN105755041A (en) 2016-07-13
US9796986B2 (en) 2017-10-24
CA2611708C (en) 2019-11-12
JP5925407B2 (en) 2016-05-25
UA99700C2 (en) 2012-09-25
SI1896590T1 (en) 2016-07-29
IL187676A (en) 2017-02-28
EP1739179A1 (en) 2007-01-03
JP2016154537A (en) 2016-09-01
US9273325B2 (en) 2016-03-01
US20100184141A1 (en) 2010-07-22

Similar Documents

Publication Publication Date Title
WO2007003582A3 (en) Serum-free stable transfection and production of recombinant human proteins in human cell lines
WO2008114673A1 (en) Method for production of polypeptide
WO2009114702A3 (en) Recombinant production of authentic human proteins using human cell expression systems
WO2008153029A1 (en) Method for expression of specific gene
PL1948789T3 (en) Method for the production of permanent human cell lineages
WO2008145133A3 (en) Method for manufacturing a recombinant polyclonal protein
TW200716753A (en) Vector
WO2010056808A3 (en) Compositions and methods for re-programming and re-differentiating cells
AU2009209251A8 (en) Stabilized Angiopoietin-2 antibodies and uses thereof
SG10201901417UA (en) Production of proteins in glutamine-free cell culture media
WO2009011258A1 (en) Method for maintaining foreign gene in cell stably
WO2014013026A8 (en) Transposition-mediated identification of specific binding or functional proteins
WO2005072129A9 (en) Production of host cells containing mutiple integrating vectors by serial transduction
IL189193A0 (en) Transplastomic plants expressing lumen-targeted protein
WO2009020144A1 (en) Method of producing heterogeneous protein
EP1963506A4 (en) Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
WO2006039622A3 (en) Feeding buffers, systems, and methods for in vitro synthesis of biomolecules
WO2007130543A3 (en) Method for producing stable mammalian cell lines producing high levels of recombinant proteins
WO2007051063A3 (en) Gpcr expressing cell lines and antibodies
UA92913C2 (en) Expression vector and methods for production of high levels of proteins
WO2007015691A3 (en) Methods and compositions for increasing longevity and protein yield from a cell culture
WO2008070273A3 (en) Methods of expressing lim mineralization protein
WO2009125999A8 (en) Human host cell for producing recombinant proteins with high quality and quantity
WO2012012271A3 (en) Novel glycosylated polypeptides
SG181862A1 (en) Protein display

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 187676

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/015370

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006777525

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2611708

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 200680023280.1

Country of ref document: CN

Ref document number: 1020077030563

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008518853

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006265173

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008103319

Country of ref document: RU

Ref document number: A200801065

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: 2006265173

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006265173

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006777525

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11993604

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0613721

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080102

WWE Wipo information: entry into national phase

Ref document number: 250575

Country of ref document: IL